Comparative Pharmacology
Head-to-head clinical analysis: ADENOCARD versus DURAQUIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADENOCARD versus DURAQUIN.
ADENOCARD vs DURAQUIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adenosine is an endogenous purine nucleoside that acts on A1 and A2 adenosine receptors. It slows conduction through the AV node, interrupts reentry pathways, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT).
Quinidine is a class Ia antiarrhythmic agent that blocks sodium channels, slowing phase 0 depolarization, prolongs the action potential duration, and increases the effective refractory period. It also exhibits anticholinergic and negative inotropic effects.
6 mg IV bolus over 1-2 seconds, followed by 20 mL saline flush; if no conversion to sinus rhythm within 1-2 minutes, give 12 mg IV bolus; may repeat 12 mg once more if needed.
Quinidine sulfate 324 mg orally every 8-12 hours, adjusted based on serum quinidine levels.
None Documented
None Documented
Terminal half-life is less than 10 seconds; clinically, the effect is very transient due to rapid cellular uptake and metabolism.
Terminal elimination half-life is 8-12 hours in adults with normal renal and hepatic function. Clinically, dose adjustment may be needed in renal impairment (half-life prolonged to up 18 hours) or hepatic impairment.
Primarily renal excretion of metabolites; adenosine is rapidly metabolized intracellularly to inosine and adenosine monophosphate, with less than 1% excreted unchanged in urine.
Primarily hepatic metabolism (90-95%) to inactive metabolites, with renal excretion of unchanged drug <5% and metabolites. Fecal elimination accounts for <5% due to biliary excretion of metabolites.
Category C
Category C
Antiarrhythmic
Antiarrhythmic